Clinicopathologic features of relapsed CD19 (−) B‐ALL in CD19 ‐targeted immunotherapy: Biological insights into relapse and LILRB1 as a novel B‐cell marker for CD19 (−) B lymphoblasts
International Journal of Laboratory Hematology · 2024-06 · 46 (3) · 503-509
DOI: 10.1111/ijlh.14226 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, online erschienen am 04.01.2024. Verfasst von Dong Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Antigens, CD19, Leukocyte Immunoglobulin-like Receptor B1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Introduction
The mechanism of relapsed CD19(−) B‐ALL after anti‐CD19 immunotherapy (Kymriah [CART‐19] and blinatumomab) is under active investigation. Our study aims to assess LILRB1 as a novel B‐cell marker for detecting CD19(−) B‐lymphoblasts and to analyze the clinicopathologic/genetic features of such disease to provide biological insight into relapse.
Methods
Six patients (3 males/3 females, median age of 14 years) with relapsed CD19(−) B‐ALL were analyzed for cytogenetic/genetic profile and immunophenotype.
Results
CD19(−) B‐ALL emerged after an interval of 5.8 months following anti‐CD19 therapy. Five of six patients had B‐cell aplasia, indicative of a persistent effect of CART or blinatumomab at relapse. Importantly, LILRB1 was variably expressed on CD19(−) and CD19(+) B lymphoblasts, strong on CD34(+) lymphoblasts and dim/partial on CD34(−) lymphoblasts. Three of six patients with paired B‐ALL samples (pre‐ and post‐anti‐CD19 therapy) carried complex and different cytogenetic abnormalities, either as completely different or sharing a subset of cytogenetic abnormalities.
Conclusion
LILRB1 can be used as a novel B‐cell marker to identify CD19(−) B lymphoblasts. The emergence of CD19(−) B‐ALL appears to be associated with complex cytogenetic evolutions. The mechanism of CD19(−) B‐ALL relapse under anti‐CD19 immune pressure remains to be explored by comprehensive molecular studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Pathology and Laboratory Medicine, University of Connecticut, Farmington, Connecticut, USA.
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
- Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
ORCID-Profile: Dong Chen, Weina Chen
Zitieren
APA
Chen, D., Fuda, F., Rosado, F., Saumell, S., John, S., Chen, M., Koduru, P., & Chen, W. (2024). Clinicopathologic features of relapsed CD19 (−) B‐ALL in CD19 ‐targeted immunotherapy: Biological insights into relapse and LILRB1 as a novel B‐cell marker for CD19 (−) B lymphoblasts. International Journal of Laboratory Hematology, 46(3), 503-509. https://doi.org/10.1111/ijlh.14226
Vancouver
Chen D, Fuda F, Rosado F, Saumell S, John S, Chen M, et al. Clinicopathologic features of relapsed CD19 (−) B‐ALL in CD19 ‐targeted immunotherapy: Biological insights into relapse and LILRB1 as a novel B‐cell marker for CD19 (−) B lymphoblasts. International Journal of Laboratory Hematology. 2024;46(3):503-509. doi:10.1111/ijlh.14226
BibTeX
@article{Chen2024,
author = {Chen, Dong and Fuda, Franklin and Rosado, Flavia and Saumell, Sílvia and John, Samuel and Chen, Mingyi and Koduru, Prasad and Chen, Weina},
title = {Clinicopathologic features of relapsed CD19 (−) B‐ALL in CD19 ‐targeted immunotherapy: Biological insights into relapse and LILRB1 as a novel B‐cell marker for CD19 (−) B lymphoblasts},
journal = {International Journal of Laboratory Hematology},
year = {2024},
volume = {46},
number = {3},
pages = {503--509},
doi = {10.1111/ijlh.14226}
}
EUVIMED